Compare Immunovant Inc. Common Stock (IMVT) vs S&P500 ETF (SPY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Immunovant Inc. Common Stock vs S&P500 ETF — how do they compare? Immunovant Inc. Common Stock trades at $30.01 (market cap $6.62B), while S&P500 ETF trades at $777.49 (market cap $819.04B). The key difference: S&P500 ETF is far larger — about 123.7× Immunovant Inc. Common Stock's market cap, and S&P500 ETF is trading nearer its 52-week high, Immunovant Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Immunovant Inc. Common Stock for 0 Days and S&P500 ETF for 205 Days on average.
| IMVT | SPY | |
|---|---|---|
Market Cap | $6.62B | $819.04B |
Volume | 1,131,364 | 30,746,070 |
Sector | Health | — |
52-Week High | $44.96 | $779.14 |
52-Week Low | $17.03 | $631.99 |
Typical Hold Time | 0 Days | 205 Days |
Enterprise Value | $5.72B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
SPY, the SPDR S&P 500 ETF, trades at $777.26, down 0.24% on the day. The technical outlook is bullish, with moving averages strongly supportive and the price above key support at $775. However, oscillators are neutral, and the 6-day RSI at 75.74 suggests potential overbought conditions. A dividend of $1.89 is scheduled for payment on October 30, 2026.
The ETF's outlook remains tied to broader S&P 500 earnings, which are projected to grow 35% in 2026 but slow to 15% in 2027. Key risks include market-wide valuation concerns and potential profit growth deceleration. Investor sentiment is mixed, with some analysts highlighting defensive positioning and seasonal patterns favoring a year-end rally.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Immunovant Inc. Common Stock
Immunovant is a clinical-stage immunology company developing therapies for autoimmune diseases. Its pipeline includes anti-FcRn antibody candidates designed for subcutaneous administration.
Read more on IMVT →About S&P500 ETF
The ETF is designed to track the performance of the securities and the stocks in the S&P 500 Index. To maintain the composition and weightings, the advisor adjusts the ETF from time to time to conform to periodic changes in the index target.
Read more on SPY →
